Cargando…

A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain

The effectiveness of a 3(rd) dose of SARS-CoV-2 vaccines waned quickly in the Omicron-predominant period. In response to fast-waning immunity and the threat of Omicron variant of concern (VOC) to healthcare workers (HCWs), we conduct a non-randomized trial (ChiCTR2200055564) in which 38 HCWs volunte...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ji, Deng, Caiguangxi, Liu, Ming, Liu, Yihao, Li, Liubing, Huang, Zhangping, Shang, Liru, Jiang, Juan, Li, Yongyong, Mo, Ruohui, Zhang, Hui, Liu, Min, Peng, Sui, Xiao, Haipeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651894/
https://www.ncbi.nlm.nih.gov/pubmed/36369243
http://dx.doi.org/10.1038/s41467-022-34633-7
_version_ 1784828330468442112
author Wang, Ji
Deng, Caiguangxi
Liu, Ming
Liu, Yihao
Li, Liubing
Huang, Zhangping
Shang, Liru
Jiang, Juan
Li, Yongyong
Mo, Ruohui
Zhang, Hui
Liu, Min
Peng, Sui
Xiao, Haipeng
author_facet Wang, Ji
Deng, Caiguangxi
Liu, Ming
Liu, Yihao
Li, Liubing
Huang, Zhangping
Shang, Liru
Jiang, Juan
Li, Yongyong
Mo, Ruohui
Zhang, Hui
Liu, Min
Peng, Sui
Xiao, Haipeng
author_sort Wang, Ji
collection PubMed
description The effectiveness of a 3(rd) dose of SARS-CoV-2 vaccines waned quickly in the Omicron-predominant period. In response to fast-waning immunity and the threat of Omicron variant of concern (VOC) to healthcare workers (HCWs), we conduct a non-randomized trial (ChiCTR2200055564) in which 38 HCWs volunteer to receive a homologous booster of inactivated vaccines (BBIBP-CorV) 6 months after the 3(rd) dose. The primary and secondary outcomes are neutralizing antibodies (NAbs) and the receptor-binding domain (RBD)-directed antibodies, respectively. The 4(th) dose recalls waned immunity while having distinct effects on humoral responses to different antigens. The peak antibody response to the RBD induced by the 4(th) dose is inferior to that after the 3(rd) dose, whereas responses to the N-terminal domain (NTD) of spike protein are further strengthened significantly. Accordingly, the 4(th) dose further elevates the peak level of NAbs against ancestral SARS-CoV-2 and Omicron BA.2, but not BA.1 which has more NTD mutations. No severe adverse events related to vaccination are recorded during the trial. Here, we show that redistribution of immune focus after repeated vaccinations may modulate cross-protective immune responses against different VOCs.
format Online
Article
Text
id pubmed-9651894
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96518942022-11-14 A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain Wang, Ji Deng, Caiguangxi Liu, Ming Liu, Yihao Li, Liubing Huang, Zhangping Shang, Liru Jiang, Juan Li, Yongyong Mo, Ruohui Zhang, Hui Liu, Min Peng, Sui Xiao, Haipeng Nat Commun Article The effectiveness of a 3(rd) dose of SARS-CoV-2 vaccines waned quickly in the Omicron-predominant period. In response to fast-waning immunity and the threat of Omicron variant of concern (VOC) to healthcare workers (HCWs), we conduct a non-randomized trial (ChiCTR2200055564) in which 38 HCWs volunteer to receive a homologous booster of inactivated vaccines (BBIBP-CorV) 6 months after the 3(rd) dose. The primary and secondary outcomes are neutralizing antibodies (NAbs) and the receptor-binding domain (RBD)-directed antibodies, respectively. The 4(th) dose recalls waned immunity while having distinct effects on humoral responses to different antigens. The peak antibody response to the RBD induced by the 4(th) dose is inferior to that after the 3(rd) dose, whereas responses to the N-terminal domain (NTD) of spike protein are further strengthened significantly. Accordingly, the 4(th) dose further elevates the peak level of NAbs against ancestral SARS-CoV-2 and Omicron BA.2, but not BA.1 which has more NTD mutations. No severe adverse events related to vaccination are recorded during the trial. Here, we show that redistribution of immune focus after repeated vaccinations may modulate cross-protective immune responses against different VOCs. Nature Publishing Group UK 2022-11-11 /pmc/articles/PMC9651894/ /pubmed/36369243 http://dx.doi.org/10.1038/s41467-022-34633-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Wang, Ji
Deng, Caiguangxi
Liu, Ming
Liu, Yihao
Li, Liubing
Huang, Zhangping
Shang, Liru
Jiang, Juan
Li, Yongyong
Mo, Ruohui
Zhang, Hui
Liu, Min
Peng, Sui
Xiao, Haipeng
A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain
title A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain
title_full A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain
title_fullStr A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain
title_full_unstemmed A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain
title_short A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain
title_sort fourth dose of the inactivated sars-cov-2 vaccine redistributes humoral immunity to the n-terminal domain
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651894/
https://www.ncbi.nlm.nih.gov/pubmed/36369243
http://dx.doi.org/10.1038/s41467-022-34633-7
work_keys_str_mv AT wangji afourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT dengcaiguangxi afourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT liuming afourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT liuyihao afourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT liliubing afourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT huangzhangping afourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT shangliru afourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT jiangjuan afourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT liyongyong afourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT moruohui afourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT zhanghui afourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT liumin afourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT pengsui afourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT xiaohaipeng afourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT wangji fourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT dengcaiguangxi fourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT liuming fourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT liuyihao fourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT liliubing fourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT huangzhangping fourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT shangliru fourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT jiangjuan fourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT liyongyong fourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT moruohui fourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT zhanghui fourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT liumin fourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT pengsui fourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain
AT xiaohaipeng fourthdoseoftheinactivatedsarscov2vaccineredistributeshumoralimmunitytothenterminaldomain